Table 2 Alemtuzumab-treated patients with positive virus PCR; virus, copy numbers (no of genome equivalents/ml) and symptoms

From: Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia

Patient (n=18)

Time point of PCR analyses

 

Baseline (n=18)

1 month (n=15)

2 months (n=13)

3 months (n=12)

End of treatment (n=18)

6 months post-therapy (n=17)

12 months post-therapy (n=17)

A4

N

N

CMV

11 600

N

N

N

N

A5

N

N

CMV

81 400

cough

N

N

N

N

A6

EBV

2000

EBV

1800a

ND

N

N

N

N

A7

EBV

2600

EBV

2000

ND

ND

N

N

N

A7

N

HHV-6

1300

ND

ND

N

N

N

A8

N

N

CMV

8600

fever

N

N

N

N

A11

N

CMV

12 900

N

N

N

N

N

A12

N

N

CMV

7900

fever

N

N

N

N

A18

EBV

2600

N

N

N

N

N

N

Total 8 (44%)

Total 3 (17%)

Total 4 (27%)

Total 4 (31%)

Total 0

Total 0

Total 0

Total 0

  1. Abbreviations: CMV, cytomegalovirus; EBV, Epstein-Barr virus; HHV-6, human herpesvirus 6; N, negative; ND, not determined.
  2. a2 weeks after start of therapy.
Back to article page